[AstraZeneca announced an investment of nearly 200 million yuan to comprehensively upgrade its Wuxi base] September 17, according to AstraZeneca China news, today, AstraZeneca announced an investment of nearly 200 million yuan to comprehensively upgrade the new drug development and supply building of the Wuxi production and supply base (hereinafter referred to as the "Wuxi Base"), which will be used for the process development and production of innovative cardiovascular drugs under development by AstraZeneca, and to support the global supply of the drug after commercialization. The project has a construction area of ​​approximately 5,800 square meters and is scheduled to be put into operation in the fourth quarter of 2029. The annual production capacity is expected to reach 400 million pieces. After completion, the Wuxi base will participate in the development of commercial production processes from the drug research and development stage, and is expected to become AstraZeneca's first base in the Asia-Pacific region with the ability to support the global launch and supply of new drugs.